Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hairy cell leukemia: an update.

Grant R Goodman1, Kelly J Bethel, Alan Saven

  • 1Division of Hematology/Oncology, Scripps Clinic, La Jolla, California 92037, USA.

Current Opinion in Hematology
|June 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Dose Vemurafenib Plus Rituximab in Front-Line and Relapsed or Refractory Hairy Cell Leukemia: The Scripps Regimen.

Blood advances·2026
Same author

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab.

British journal of haematology·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

Leukemia & lymphoma·2025
Same author

Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.

Leukemia & lymphoma·2025
Same author

Hairy-Cell Leukemia.

The New England journal of medicine·2024
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Hairy cell leukemia (HCL) is a rare B-cell cancer. Treatment is recommended for symptomatic patients, with options including chemotherapy and immunotherapy.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoproliferative disorder, accounting for 2-3% of adult leukemias in the U.S.
  • Hairy cells are characterized as clonal expansions of mature, activated B-cells expressing specific markers (CD11c, CD19, CD20, CD22, CD25, CD103).
  • These cells exhibit clonal immunoglobulin gene rearrangements and express monoclonal surface immunoglobulin.

Purpose of the Study:

  • To summarize the characteristics and treatment indications for Hairy Cell Leukemia.
  • To outline the available therapeutic options for managing HCL.

Main Methods:

  • Literature review of HCL characteristics and treatment guidelines.
  • Analysis of patient criteria for initiating HCL therapy.

Related Experiment Videos

  • Compilation of current treatment modalities for HCL.

    • Main Results:

    • HCL is a distinct B-cell leukemia with specific immunophenotypic and molecular features.
    • Treatment is indicated for patients with symptomatic disease, including cytopenias, splenomegaly, constitutional symptoms, or infections.
    • Established treatments include cladribine, pentostatin, interferon-alpha, splenectomy, rituximab, and BL-22 immunotoxin.

    Conclusions:

    • Hairy cell leukemia requires specific treatment considerations for symptomatic individuals.
    • A range of effective therapeutic agents are available for managing HCL.
    • Timely intervention based on clinical indicators is crucial for patient management.